{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:38:00Z","timestamp":1784335080002,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["humanpathol.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.humpath.2016.03.010","type":"journal-article","created":{"date-parts":[[2016,4,10]],"date-time":"2016-04-10T03:05:19Z","timestamp":1460257519000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma"],"prefix":"10.1016","volume":"54","author":[{"given":"Dag Andre","family":"Nymoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Slipicevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arild","family":"Holth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Emilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea E.","family":"Hetland Falkenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claes G.","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuven","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivi Ann","family":"Fl\u00f8renes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2016.03.010_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.humpath.2016.03.010_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0020","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.humpath.2015.06.013","article-title":"MicroRNAs in ovarian cancer","volume":"46","author":"Katz","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0025","doi-asserted-by":"crossref","first-page":"e58226","DOI":"10.1371\/journal.pone.0058226","article-title":"Identification of ovarian cancer metastatic miRNAs","volume":"8","author":"Vang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2016.03.010_bb0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1476-4598-7-35","article-title":"Potential role of miR-9 and miR-223 in recurrent ovarian cancer","volume":"7","author":"Laios","year":"2008","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2016.03.010_bb0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/j.1582-4934.2010.01148.x","article-title":"miRNA profiling along tumor progression in ovarian carcinoma","volume":"15","author":"Vaksman","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.humpath.2016.03.010_bb0040","doi-asserted-by":"crossref","first-page":"R64","DOI":"10.1186\/gb-2009-10-6-r64","article-title":"A novel and universal method for microRNA RT-qPCR data normalization","volume":"10","author":"Mestdagh","year":"2009","journal-title":"Genome Biol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0045","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","article-title":"Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study","volume":"12","author":"Thigpen","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0050","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2016.03.010_bb0055","doi-asserted-by":"crossref","first-page":"12837","DOI":"10.18632\/oncotarget.3805","article-title":"miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies","volume":"6","author":"Amodio","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2016.03.010_bb0060","doi-asserted-by":"crossref","first-page":"294","DOI":"10.18632\/oncoscience.143","article-title":"P18\/Stathmin1 is regulated by miR-31 in ovarian cancer in response to taxane","volume":"2","author":"Hassan","year":"2015","journal-title":"Oncoscience"},{"key":"10.1016\/j.humpath.2016.03.010_bb0065","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/path.4000","article-title":"MiR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma","volume":"228","author":"Liu","year":"2012","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0070","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00428-012-1228-9","article-title":"HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases","volume":"460","author":"Hetland","year":"2012","journal-title":"Virchows Arch"},{"key":"10.1016\/j.humpath.2016.03.010_bb0075","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ygyno.2008.08.036","article-title":"The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform","volume":"112","author":"Resnick","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/ijc.28399","article-title":"Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells","volume":"134","author":"Yu","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.humpath.2016.03.010_bb0085","doi-asserted-by":"crossref","first-page":"e34546","DOI":"10.1371\/journal.pone.0034546","article-title":"Cancer Genome Atlas Research Network. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma","volume":"7","author":"Creighton","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2016.03.010_bb0090","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.humpath.2014.02.008","article-title":"Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma","volume":"45","author":"Dai","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0095","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/IGC.0b013e3181a48cf9","article-title":"miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma","volume":"19","author":"Flavin","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2016.03.010_bb0100","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/oncsis.2013.3","article-title":"Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET","volume":"2","author":"Mitamura","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.humpath.2016.03.010_bb0105","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-09-3875","article-title":"Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers","volume":"70","author":"Creighton","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2016.03.010_bb0110","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jcb.24488","article-title":"MicroRNA-182 promotes cell growth, invasion, and chemoresistance by targeting programmed cell death 4 (PDCD4) in human ovarian carcinomas","volume":"114","author":"Wang","year":"2013","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.humpath.2016.03.010_bb0115","series-title":"Serous Effusions\u2014Etiology, Diagnosis, Prognosis and Therapy","first-page":"167","article-title":"Ovarian and primary peritoneal carcinoma","author":"Davidson","year":"2011"},{"key":"10.1016\/j.humpath.2016.03.010_bb0120","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s00109-013-1055-8","article-title":"HMGA2 and high-grade serous ovarian carcinoma","volume":"91","author":"Wu","year":"2013","journal-title":"J Mol Med"},{"key":"10.1016\/j.humpath.2016.03.010_bb0125","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1517\/14728222.2011.620951","article-title":"Stathmin: a protein with many tasks. New biomarker and potential target in cancer","volume":"15","author":"Belletti","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.humpath.2016.03.010_bb0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2011.05.021","article-title":"Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas","volume":"123","author":"Karst","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0135","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2015.07.100","article-title":"Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma","volume":"139","author":"Novak","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2016.03.010_bb0140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1186\/1471-2407-14-576","article-title":"Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor","volume":"14","author":"Lv","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2016.03.010_bb0145","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cncr.24282","article-title":"Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel","volume":"115","author":"Su","year":"2009","journal-title":"Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716300259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817716300259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T13:53:55Z","timestamp":1536846835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817716300259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":29,"alternative-id":["S0046817716300259"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2016.03.010","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2016.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}